Kisqali (ribociclib) costs roughly $7,500 to $11,000 per month depending on the dose, placing it among the most expensive oral cancer medications on the market. Several factors drive this price: the cost of developing and testing the drug through multiple large clinical trials, patent protection that prevents generic competition until 2036, and a pricing landscape where all drugs in this class carry similarly high price tags.
What Kisqali Actually Costs
The wholesale acquisition cost for a 28-day supply of Kisqali at the standard 600 mg daily dose is $10,950. Lower doses cost proportionally less: $8,760 for the 400 mg dose and $4,380 for the 200 mg dose. Without insurance, a single pack of 21 tablets at the 200 mg strength runs about $7,470.
These are list prices before insurance. What you actually pay depends entirely on your coverage. In Medicare Part D, Kisqali lands on the specialty tier 100% of the time in standalone prescription drug plans, which typically means coinsurance of 25% to 33% rather than a flat copay. Some Medicare Advantage Special Needs Plans place it on the preferred brand tier instead, which can lower out-of-pocket costs. But even with insurance, the monthly bill can reach hundreds or thousands of dollars.
No Generic Competition Until 2036
Kisqali’s primary patent doesn’t expire until April 2036, according to FDA records. That gives Novartis more than a decade of market exclusivity from the drug’s original 2017 approval. During that window, no other company can manufacture a generic version of ribociclib, which means there’s no price pressure from cheaper alternatives.
This is standard for brand-name cancer drugs. Patent protection is designed to let pharmaceutical companies recoup their investment in research and development before competitors enter the market. The tradeoff is that patients and insurers pay premium prices for years. Once generics eventually arrive, prices for similar drugs have historically dropped by 80% or more.
Every Drug in This Class Is Expensive
Kisqali belongs to a class of drugs called CDK4/6 inhibitors, and all three approved options carry comparable price tags. Verzenio (abemaciclib) costs about $4,235 for a 14-tablet supply at its lowest strength, scaling up with higher doses. Ibrance (palbociclib), the first drug in this class, has historically priced in the same range.
When all competitors price similarly, there’s little market incentive for any manufacturer to lower its price. Oncologists choose among these drugs based on clinical data, side effect profiles, and individual patient factors, not cost. This removes the kind of price competition that drives costs down in other medication categories. Novartis can price Kisqali in line with its competitors without losing market share.
The Cost of Clinical Development
Kisqali’s approval and expanded uses were built on the MONALEESA program, a series of three large, international clinical trials. MONALEESA-2 tested the drug alongside an aromatase inhibitor in postmenopausal women. MONALEESA-3 studied it with a different hormonal therapy. MONALEESA-7 focused specifically on premenopausal women, a population previously underserved by this drug class. These trials collectively enrolled thousands of patients across dozens of countries and ran for years to demonstrate both progression-free survival and overall survival benefits.
Running trials of this scale is extraordinarily expensive. While Novartis hasn’t disclosed the exact cost of the MONALEESA program, industry estimates for bringing a cancer drug from discovery through Phase III trials and FDA approval typically range from $1 billion to over $2 billion. That investment gets baked into the drug’s price over its patent life. Kisqali’s recent expanded approval as a standalone treatment for early-stage breast cancer further required additional trial data, adding to development costs that Novartis factors into its pricing strategy.
Cost-Effectiveness Varies Widely
Health economists evaluate whether a drug’s price is justified by measuring how much it costs per quality-adjusted life year gained. In the United States, the average cost-effectiveness ratio for Kisqali has been estimated at over $813,000 per quality-adjusted life year. That figure is far above the commonly used threshold of $100,000 to $150,000 per quality-adjusted life year that’s generally considered acceptable value in the U.S. healthcare system. By comparison, the same analysis found the ratio in Spain was just $1,863 per quality-adjusted life year, reflecting dramatically lower drug prices in countries with government-negotiated pricing.
This gap highlights a core reason Kisqali is so expensive specifically in the United States. Unlike most other high-income countries, the U.S. does not negotiate drug prices at a national level for most patients. Manufacturers set their own prices, and insurers negotiate individually. The result is that Americans pay several times more for the same medication than patients in Europe or other regions.
Options for Reducing Your Cost
The Novartis Patient Assistance Foundation provides Kisqali at no cost to eligible patients who are uninsured or have government insurance and meet income guidelines. You’ll need to submit proof of income and may need to show you’ve been denied Extra Help (the Medicare low-income subsidy). The program is limited to U.S. residents being treated on an outpatient basis by a licensed provider.
Novartis also offers a separate copay assistance program for commercially insured patients, which can reduce out-of-pocket costs to a lower monthly amount. If you have Medicare or Medicaid, you won’t qualify for copay cards, but you may qualify for the patient assistance foundation or other independent nonprofit funds that help cover cancer drug costs. Your oncology team’s financial navigator or social worker can help identify which programs apply to your specific insurance situation.